ProfileGDS5672 / 211812_s_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [HG-U133_Plus_2]
OrganismHomo sapiens


control bevacizumab dibenzazepine GSM958322 GSM958323 GSM958324 GSM958328 GSM958329 GSM958330 GSM958325 GSM958326 GSM958327 83% 82% 84% 83% 84% 84% 82% 82% 82% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM958322U87-EV human glioblastoma xenograft - Control - 1 [HG-U133_Plus_2]8.670983
GSM958323U87-EV human glioblastoma xenograft - Control - 2 [HG-U133_Plus_2]8.4008882
GSM958324U87-EV human glioblastoma xenograft - Control - 3 [HG-U133_Plus_2]8.7307984
GSM958328U87-EV human glioblastoma xenograft - Bevacizumab treated - 1 [HG-U133_Plus_2]8.5411283
GSM958329U87-EV human glioblastoma xenograft - Bevacizumab treated - 2 [HG-U133_Plus_2]8.650384
GSM958330U87-EV human glioblastoma xenograft - Bevacizumab treated - 3 [HG-U133_Plus_2]8.6402584
GSM958325U87-EV human glioblastoma xenograft - dibenzazepine treated - 1 [HG-U133_Plus_2]8.432282
GSM958326U87-EV human glioblastoma xenograft - dibenzazepine treated - 2 [HG-U133_Plus_2]8.3659182
GSM958327U87-EV human glioblastoma xenograft - dibenzazepine treated - 3 [HG-U133_Plus_2]8.3710482